Skip to content

Zambia Healthy Choices Project for Emerging Adults Living With HIV

Adapting mHealth Interventions to Improve Self-management of HIV and Substance Use Among Emerging Adults in Zambia

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06415357
Enrollment
164
Registered
2024-05-16
Start date
2024-04-20
Completion date
2026-07-31
Last updated
2026-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pre-Exposure Prophylaxis

Keywords

Pre-Exposure Prophylaxis (PrEP), HIV Prevention, mHealth

Brief summary

This project will develop and implement a multi-component intervention using mobile health technology to improve HIV self-management and reduce substance use. Specifically, the investigators will adapt Healthy Choices (HC) to develop mobile HC (mHC) and develop Motivational text messaging (MTM) for Zambian emerging adults living with HIV.

Interventions

mHC is a four-session computer-delivered intervention based on the Information-Motivation-Behavioral (IMB) model and socioecological model (SEM). Using motivational interviewing, it tailors content to participants' responses. Sessions 1 and 2 focus on HIV self-management and alcohol reduction, gauging importance, confidence, and goals. Strengths, barriers, resources, and strategies are explored. Sessions 3 and 4 review goals, reinforce importance, confidence, and motivation, and strategize behavior maintenance. Over two months, participants engage in goal-oriented sessions, promoting sustained behavior change.

BEHAVIORALMotivational Text Messaging (MTM)

Text messages with motivational statements will be sent to participants based on their readiness to change, as assessed during mHC session 1. The statements promoting HIV self-management and alcohol use reduction will be derived from an MTM library written by Zambian young people living with HIV. MTM will be delivered to participants daily for two months and weekly for an additional four months at a time that a participant prefers.

BEHAVIORALStandard ART Counseling

All participants will receive one-on-one, face-to-face in clinic. Standard ART counseling includes the management and treatment of HIV, reproductive health, substance abuse, and mental health. They will also be counseled about treatment adherence and side-effect management.

Sponsors

University of Massachusetts, Worcester
Lead SponsorOTHER
National Institute on Drug Abuse (NIDA)
CollaboratorNIH
University of Zambia
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 24 Years
Healthy volunteers
Yes

Inclusion criteria

Zambian emerging adults living with HIV Inclusion Criteria: * Aged between 18 and 24 years * Report visual analogue scale showing \<80% medication adherence in the last month AND problematic/risky alcohol use in the last month * Speak English, Nyanja, or Bemba

Exclusion criteria

* Have a serious cognitive or psychiatric problem that would compromise ability to provide informed consent * currently enrolled in another HIV intervention study

Design outcomes

Primary

MeasureTime frameDescription
Intervention Acceptability: System Usability Score (SUS)Month 3SUS is a 10-item, 5-point Likert scale for subjective assessment of usability. Each item ranges from 1 to 5. Depending on the item, the score is calculated by subtracting either one from the user response or the user response from 5. Then, the score for each item will be summed and multiplied by 2.5 for the total score. The overall SUS scores range from 0 to 100. A score of \> 50 indicates that the technology-based interventions are acceptable.
Intervention Acceptability: Client Satisfaction Questionnaire (CSQ-8)Month 3CSQ-8 is an 8-item, 4-point Likert scale measuring the construct of global intervention satisfaction. The total possible composite score ranges from 8 to 32, with higher scores indicating greater acceptability.
Intervention Acceptability: Exit InterviewMonth 3Participants will be invited to share their experiences with mHC and MTM, including feedback on acceptability, ease of use, suggestions for improvement, and impact on ART adherence and alcohol use reduction.
Intervention Feasibility: Participant RetentionBaseline to Month 6Intervention feasibility will be assessed based on participant retention at Month 6. The retention rate can range from 70 to 90%, with a retention rate of over 85% deemed the minimum criterion for feasibility.
Intervention Feasibility: Number of Responses to MTMBaseline to Month 6Intervention feasibility will be evaluated by the total number of responses to MTM.
Intervention Feasibility: Number of mHC Sessions CompletedBaseline to Month 6Intervention feasibility will be evaluated by the number of completed intervention sessions.
ART Adherence: Visual Analog ScaleBaseline, Month 3, and Month 6ART adherence will be assessed through the Young Adult Adherence Interview via computer-assisted self-interview (CASI) survey, which contains a visual analog scale (VAS) ranging from 0 to 100. Higher percentages on the VAS indicate greater adherence to ART.
ART Adherence: Self-Reported AdherenceBaseline, Month 3, and Month 6ART adherence will be evaluated through self-reported adherence over the past four weeks via a CASI survey. Participants will rate their adherence on a scale ranging from 0 to 100%, with higher percentages indicating better adherence to ART.
ART Adherence: Dried Blood Spot (DBS) TestingBaseline, Month 3, and Month 6ART adherence will be evaluated by examining the HIV viral load in DBS. Maintaining a viral load of less than 200 copies/ml will indicate adherence to ART.
Alcohol Use: The Timeline Followback (TLFB) InterviewBaseline, Month 3, and Month 6Alcohol use will be assessed using the TLFB interview. Using a calendar, participants will be asked to provide estimates of their daily drinking over the last 30 days, as well as the max number of drinks in a one-week period, the number of heavy drinking days, the number of standard drinks in 30 days, and binge drinking.

Secondary

MeasureTime frameDescription
Information: HIV KnowledgeBaseline, Month 3, and Month 6HIV transmission risk awareness will be evaluated through an 18-item HIV Knowledge Questionnaire. Total possible composite scores range from 0 to 18, with higher scores indicating a higher level of HIV knowledge.
Information: ART KnowledgeBaseline, Month 3, and Month 6ART knowledge will be evaluated through a 21-item HIV Treatment Knowledge Questionnaire. Total possible composite scores range from 0 to 21, with higher scores indicating a higher level of ART knowledge.
Motivation: Rollnick's Readiness RulerBaseline, Month 3, and Month 6Intentions to improve HIV self-management and alcohol consumption behaviors will be evaluated using the 5-item Rollnick's Readiness Ruler. Each item ranges from 0 to 10, with higher scores indicating a greater readiness for change.
Motivation: Decisional Balance for Problem BehaviorBaseline, Month 3, and Month 6Attitudes toward risk behaviors will be assessed using the 32-item Decisional Balance for Problem Behavior scale. This 5-point Likert scale evaluates the perceived pros and cons of engaging in risk behaviors
Behavioral Skills: Self-EfficacyBaseline, Month 3, and Month 6Behavioral skills in HIV self-management will be assessed using a 5-item adapted version of the Self-Efficacy for Health Promotion and Risk Reduction Questionnaire. This 5-point Likert scale measures confidence levels (score range: 5-25), with higher scores indicating greater confidence in HIV self-management tasks.
STI Diagnosis: Number of participants who are diagnosed with syphilis, gonorrhea, or chlamydiaBaseline and Month 6Syphilis testing will employ a treponemal test with rapid plasma reagin (RPR), while gonorrhea and chlamydia testing will utilize pooled urine, oropharyngeal, and rectal swabs.
Sexual RiskBaseline, Month 3, and Month 6Sexual risk will be assessed using TLFB interview via CASI, capturing sexual behavior over the past 30 days, such as condom usage and the number of sexual partners.
Drug Use: Alcohol, Smoking and Substance Involvement Screening Test (ASSIST)Baseline, Month 3, and Month 6Drug use will be assessed with ASSIST, which is a questionnaire to identify substance use health risks and disorders, with each item scored from 0 to 12. The total score ranges up to 24, with higher scores indicating greater risk based on current substance use patterns.
Drug Use: Alcohol Use Disorder Identification Text (AUDIT-C)Baseline, Month 3, and Month 6Alcohol use will be assessed by using AUDIT-C to identify individuals with hazardous drinking habits or alcohol use disorders. Each item scores from 0 to 4, with 0 indicating no alcohol consumption. The total score maxes out at 12, with higher scores suggesting greater risks of harm.
Mental health: Brief Symptom Inventory (BSI-18)Baseline, Month 3, and Month 6Mental health will be evaluated with BSI-18. This 18-item questionnaire utilizes a 5-point Likert scale to gauge psychological distress. Scores range up to 72, with higher scores indicating a higher level of psychological distress.
Social support: Social Provision ScaleBaseline, Month 3, and Month 6Social support will be evaluated using the Social Provision Scale. This 5-point Likert scale, 13-item survey assesses the availability of social support, such as emotional, information, and instrumental support, as well as companionship and social isolation. Scores range up to 65, with higher scores indicating more extensive availability of social support.
HIV stigma: Shortened Version of Berger's Stigma ScaleBaseline, Month 3, and Month 6HIV-related stigma will be evaluated using the 10-item Berger's Stigma Scale. This scale, based on a 4-point Likert scale, assesses the stigma perceived by people living with HIV. The score can range from 10 to 40, with a higher score indicating greater perceived stigma associated with HIV.

Countries

Zambia

Contacts

PRINCIPAL_INVESTIGATORBo Wang, PhD

University of Massachusetts, Worcester

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 1, 2026